Compare Genuine Parts Company (GPC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Mesoblast Limited — how do they compare? Genuine Parts Company trades at $127.96 (market cap $17.67B), while Mesoblast Limited trades at $14.06 (market cap $1.75B). The key difference: Genuine Parts Company is far larger — about 10.1× Mesoblast Limited's market cap, and Genuine Parts Company pays a 3.32% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Mesoblast Limited for 14 Days on average.
| GPC | MESO | |
|---|---|---|
Market Cap | $17.67B | $1.75B |
Volume | 1,079,458 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $20.96 |
52-Week Low | $92.47 | $13.19 |
Typical Hold Time | 75 Days | 14 Days |
Enterprise Value | $23.76B | $1.83B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.
The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
